use m- iodobenzylguanidin treatment malign pheochromocytoma efficaci safeti m- iodobenzylguanidin mibg patient malign pheochromocytoma nonrandom singl arm trial patient mibg SA megabequerel/mg month patient bone soft tissu metastas soft metastas bone metastas follow-up period month number dose mci gigabequerel gbq mci /administr cumul activ gbq mci absorb cumul dose tumor Gy benefici effect treatment patient complet remiss diseas seven patient studi treatment seven hormon respons complet partial durat month patient month patient partial tumor respons soft tissu durat month patient hormon respons object improv clinic statu blood pressur clear-cut relationship cumul dose respons main side-effect patient widespread bone metastas dose gbq pancytopenia treatment studi mibg treatment effect patient advanc malign pheochromocytoma 